Pulse Biosciences (Nasdaq:PLSE) announced today that it appointed Paul A. LaViolette, co-chair of its board, as its new CEO.

Acknowledging the disparity in pulse oximetry implicates a $2 billion industry that has faced stricter regulations in recent ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ ...

The FDA's draft recommendations for pulse oximeters aims to include clinical studies involving at least 150 participants with ...

MultiPulse laser technology is the result of extensive medical experience gained over many years of research in the field of surgery. The CO2 laser, introduced into surgery over thirty years ago ...

Android 15 update is said to bring a more sophisticated notification control system, enhancing customisation to minimise ...

The FDA aims to enhance pulse oximeter accuracy for patients of colour by requiring more diverse data in studies. This change ...

Zynex's NiCO pulse oximeter utilizes highly precise laser technology to measure blood oxygenation levels directly, as opposed to current pulse oximeter products, which only estimate oxygenation ...